Genentech BioOncology

Search

Clinical Trials

At Genentech, we are committed to developing therapies for unmet needs in cancer treatment. We believe that studying the biological pathways involved in cancer development, progression, and metastasis holds the key to identifying promising molecular targets. For example, this rational approach to therapeutic development allowed us to understand angiogenesis as a key process in cancer progression, identify and clone VEGF as a key mediator in angiogenesis, and develop a humanized monoclonal antibody directed at this target.

Genentech BioOncology also supports the development of clinical diagnostics to identify patients most likely to benefit from treatment with our agents. Scientists at Genentech are investigating potential diagnostic markers, including HER receptors and ligands, using a polymerase chain reaction process that may aid selection of the patients most likely to benefit from our other targeted therapies.¹

The philosophy of Genentech BioOncology in focusing on both the basic biology of cancer and its application to therapeutics in oncology continues to drive our program of groundbreaking scientific discovery and the identification of novel targets and molecules for therapeutic development.

Ongoing Clinical Trials

The Clinical Trials chart provides information about current clinical trials involving Genentech BioOncology molecules.

Click on a column header in the chart to sort by that column.

Products under investigational study have not been approved by the FDA for the use under investigation. This information is presented only for purposes of providing a general overview of developmental stages and should not be construed as a recommendation for use of any product for unapproved uses.

Last updated: May 2008

    * Products under investigational study have not been approved by the FDA for the use under investigation. This information is presented only for purposes of providing a general overview of developmental stages and should not be construed as a recommendation for use of any product for unapproved uses.
   ** Preparing for Phase.
  *** Our collaborator Biogen Idec disagrees with certain of our development decisions under our 2003 collaboration agreement related to humanized anti-CD20 products. We continue to pursue a resolution of our differences with Biogen Idec. The disputed issues were submitted to arbitration in San Francisco, California. Resolution of the arbitration could require that both parties agree to certain development decisions before moving forward with humanized anti-CD20 antibody clinical trials, and possibly clinical trials of other collaboration products, including Rituxan, in which case we may have to alter or cancel planned trials in order to obtain Biogen Idec's approval.
 **** This molecule is being developed in collaboration with Amgen, Inc. and Immunex, a wholly owned subsidiary of Amgen, Inc.

More Information

• Genentech Clinical Trial Information Line: The Clinical Trial Information Line is available from 6 AM to 3 PM, Pacific Time, every business day, at 888-662-6728.

• www.ClinicalTrials.gov: This Web site provides regularly updated information about federally and privately supported clinical research, including information about a trial's purpose, who may participate, locations, and phone numbers for more details.

• Additional Resources: Click here to access additional information about clinical trials.

Next: Clinical Trials Resources

References

1. Amler L, Gordon MS, Strauss A, et al. Identification of predictive markers of clinical activity from a phase II trial of single agent pertuzumab (rhuMab), a HER dimerization inhibitor, in advanced ovarian cancer (OC). J Clin Oncol. 2006;24 (June 20 Suppl.):3001.